Aprea Therapeutics Q1 2025 10-Q Filed
Ticker: APRE · Form: 10-Q · Filed: May 14, 2025 · CIK: 1781983
| Field | Detail |
|---|---|
| Company | Aprea Therapeutics, Inc. (APRE) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, quarterly-report
TL;DR
Aprea Therapeutics Q1 2025 10-Q: Assets $5.5M, Liabilities $56K. Stock activity noted.
AI Summary
Aprea Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $5,512,656 and total liabilities of $56,227. Key financial activities during the first quarter of 2025 included an "At Market Offering" and transactions related to common stock and preferred stock.
Why It Matters
This filing provides a snapshot of Aprea Therapeutics' financial health and operational activities as of March 31, 2025, which is crucial for investors to assess the company's current standing.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Aprea Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition, which are not fully detailed in this summary but are typical for the industry.
Key Numbers
- $5.51M — Total Assets (As of March 31, 2025)
- $56.23K — Total Liabilities (As of March 31, 2025)
Key Players & Entities
- Aprea Therapeutics, Inc. (company) — Filer of the 10-Q
- March 31, 2025 (date) — End of the reporting period
- $5,512,656 (dollar_amount) — Total assets as of March 31, 2025
- $56,227 (dollar_amount) — Total liabilities as of March 31, 2025
FAQ
What was the net income or loss for Aprea Therapeutics for the quarter ending March 31, 2025?
The provided excerpt does not contain information on net income or loss for the quarter ending March 31, 2025.
What were the specific details of the 'At Market Offering' mentioned in the filing?
The filing indicates an 'At Market Offering' occurred between January 1, 2025, and March 31, 2025, but specific details such as the amount raised or shares issued are not present in this excerpt.
How has Aprea Therapeutics' cash position changed from the previous fiscal year-end?
The excerpt shows total assets of $5,512,656 as of March 31, 2025, but does not provide a comparative figure for the previous fiscal year-end (December 31, 2024) to determine the change in cash position.
What is the par value of Aprea Therapeutics' common stock?
The filing mentions 'us-gaap:CommonStockMember' and 'us-gaap:AdditionalPaidInCapitalMember' for the period January 1, 2025, to March 31, 2025, but the par value of the common stock is not explicitly stated in this excerpt.
Are there any significant changes in the company's debt structure reported in this 10-Q?
The filing lists total liabilities as $56,227 as of March 31, 2025, but does not provide a breakdown of the debt structure or indicate any significant changes in this excerpt.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding Aprea Therapeutics, Inc. (APRE).